Results
1195
Companies which are more than 50% undervalued based on analyst price target.
1,195 companies
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
IEP | US$9.92 | 2.8% | -53.3% | US$5.0b | US$15.00 | PS0.5x | E182.3% | 20.2% | Capital Goods | ||
IONS | US$31.04 | -1.4% | -30.1% | US$4.9b | US$61.32 | PS6.1x | E40.4% | n/a | Pharmaceuticals & Biotech | ||
MOD | US$92.68 | -6.2% | 15.6% | US$4.9b | US$147.35 | PE30.4x | E30.0% | n/a | Automobiles | ||
COTY | US$5.58 | -17.6% | -53.1% | US$4.9b | US$8.68 | PE16219.1x | E73.3% | 0% | Household | ||
PVH | US$77.71 | 0.4% | -41.0% | US$4.3b | US$121.07 | PE6.1x | E6.6% | 0.2% | Consumer Durables | ||
CNR | US$79.44 | -7.1% | 0.6% | US$4.3b | US$122.67 | PE10.5x | E14.7% | 1.3% | Energy | ||
CRSP | US$49.72 | 26.2% | -39.5% | US$4.3b | US$83.60 | PS114.3x | E51.1% | n/a | Pharmaceuticals & Biotech | ||
BHVN | US$41.43 | 8.3% | -16.3% | US$4.2b | US$66.07 | PB13.3x | E28.6% | n/a | Pharmaceuticals & Biotech | ||
CPA | US$97.78 | 8.2% | -1.3% | US$4.0b | US$147.60 | PE6.6x | E8.1% | 6.6% | Transportation | ||
LBTY.A | US$11.03 | -0.5% | -39.1% | US$4.0b | US$19.49 | PS0.5x | E42.0% | 91.2% | Telecom | ||
RARE | US$42.49 | -5.1% | -13.1% | US$3.9b | US$90.74 | PS7x | E63.3% | n/a | Pharmaceuticals & Biotech | ||
RNA | US$32.31 | -5.8% | 127.9% | US$3.9b | US$67.91 | PS381x | E34.3% | n/a | Pharmaceuticals & Biotech | ||
AKRO | US$50.52 | -1.2% | 141.8% | US$3.9b | US$78.27 | PB5.2x | E16.7% | n/a | Pharmaceuticals & Biotech | ||
MMS | US$67.85 | -2.7% | -18.5% | US$3.8b | US$102.00 | PE13.5x | E7.3% | 1.8% | Commercial Services | ||
ADMA | US$15.90 | -4.6% | 201.1% | US$3.8b | US$24.27 | PE55.2x | E26.7% | n/a | Pharmaceuticals & Biotech | ||
PRCT | US$67.61 | -3.1% | 35.3% | US$3.7b | US$102.75 | PS18.3x | E48.1% | n/a | Healthcare | ||
ALIT | US$6.76 | 0.4% | -29.4% | US$3.6b | US$10.56 | PS1.1x | E136.6% | 2.4% | Commercial Services | ||
ACLX | US$65.23 | -2.6% | 6.3% | US$3.5b | US$116.38 | PS22.6x | E22.5% | n/a | Pharmaceuticals & Biotech | ||
CORZ | US$12.51 | -2.4% | 235.4% | US$3.5b | US$20.60 | PS6.3x | E88.6% | n/a | Software | ||
IMVT | US$20.33 | 4.1% | -45.2% | US$3.5b | US$49.42 | PB9.8x | E9.2% | n/a | Pharmaceuticals & Biotech | ||
APLS | US$27.40 | -4.5% | -60.2% | US$3.4b | US$46.10 | PS4.8x | E61.3% | n/a | Pharmaceuticals & Biotech | ||
VKTX | US$30.48 | 1.0% | -15.8% | US$3.4b | US$99.29 | PB3.9x | E-4.6% | n/a | Pharmaceuticals & Biotech | ||
NFE | US$12.15 | -2.2% | -62.7% | US$3.3b | US$18.57 | PE17.3x | E-101.5% | 28.0% | Energy | ||
CRNX | US$35.21 | -3.6% | -6.9% | US$3.3b | US$75.43 | PS3142.7x | E29.8% | n/a | Pharmaceuticals & Biotech |